Skip to content

News

Phase II Study Shows No Improvement in PFS with Addition of...

Phase II Study Shows No Improvement in PFS with Addition of Pertuzumab

A study of 149 women with platinum sensitive ovarian cancer, half treated with carboplatin and paclitaxel or gemcitabine, half with that treatment plus pertuzumab, showed that the addition of pertuzumab to chemotherapy did not significantly increase progression free survival (PFS). However, the drug was described as “well-tolerated” and did not appear to increase the risk … Continued

Ovarian Cancer Research Fund Awards Over $6 Million in 2013...

Ovarian Cancer Research Fund Awards Over $6 Million in 2013 Grants

OCRF receives record number of research grant applications; launches national patient support program with new educational grants New York, NY January 10, 2013 — Ovarian Cancer Research Fund (OCRF) has awarded over $5.9 million in scientific research grants for ovarian cancer this year. Additionally, two educational and support grants totaling $100,000 were given to new … Continued

Meet OCRF’s 2013 Research Grant Recipients

Meet OCRF’s 2013 Research Grant Recipients

OCRF has awarded nearly $6 million in grants for ovarian cancer research this year. After receiving over 170 applications – the highest number in its history, for the second year in a row – OCRF and its prestigious Scientific Advisory Committee endeavored first and foremost to fund the best science. The Committee evaluated each proposal … Continued

DNA from Pap Smears Could Help Detect Endometrial and Ovari...

DNA from Pap Smears Could Help Detect Endometrial and Ovarian Cancer

1/09/2013 Analyzing DNA from Pap smears could help detect endometrial and ovarian cancer, a new study published Jan. 9, 2013 in Science Translational Medicine reports. OCRF Scientific Advisory Committee member (and former grantee) Doug Levine, MD, was among the authors of the article, which was highlighted on the cover of the journal. The routine Pap smear, which allows … Continued

New Research on Screening for Familial Ovarian Cancer

New Research on Screening for Familial Ovarian Cancer

1/3/2013 In the most recent edition of the Journal of Clinical Oncology, researchers in the UK published preliminary results from the United Kingdom Familial Ovarian Cancer Screen Study, a large trial testing the hypothesis that ovarian cancer screening may benefit women at familial risk.  Results showed that annual screening did lead to diagnosis at an earlier stage, … Continued

No Long-Term Survival Benefit for BRCA Mutation Carriers

No Long-Term Survival Benefit for BRCA Mutation Carriers

01/01/2013 Previous studies have suggested that BRCA mutation carriers with ovarian cancer have better survival rates than women who are not carriers.  Researchers in Canada and the US sought to investigate long-term survival (10 years post diagnosis) in BRCA mutation carriers.  Their results show that “for women with invasive ovarian cancer, the short-term survival advantage of … Continued

Under the Microscope: OCRF’s 2012 Research Progress R...

Under the Microscope: OCRF’s 2012 Research Progress Report

12/11/12 | In 2012, hardworking, dedicated OCRF scientists made significant advances in the fight against ovarian cancer. Below is just a sample of some of the exciting discoveries made by OCRF-funded researchers this year. With your generous support, OCRF grantees have: Thank you for supporting our mission to fund scientific research that will lead to … Continued

Metformin May Increase Survival For Women With Ovarian Cancer

Metformin May Increase Survival For Women With Ovarian Cancer

Metformin, a drug used to treat diabetes and polycystic ovarian syndrome (PCOS), may increase survival for women with ovarian cancer. A study of 239 women with ovarian cancer divided them into two arms: those with diabetes who were taking metformin and those who did not have diabetes.  More women with diabetes lived longer. Read the … Continued

Hospice Reimbursement May Disincentivize Care for Expensive...

Hospice Reimbursement May Disincentivize Care for Expensive Patients

A study by the Commonwealth Foundation found that patients with expensive treatment, such as palliative chemotherapy, were more likely to be turned away from hospice facilities. Some findings include The study found 61 percent of hospices would not accept patients who wanted chemotherapy, which can be used to help ease their pain in their dying … Continued

Common Diabetes Drug May Boost Ovarian Cancer Survival

Common Diabetes Drug May Boost Ovarian Cancer Survival

12/03/2012 Researchers at the Mayo Clinic have shown that ovarian cancer patients who were taking the common diabetes drug metformin survived longer than patients who weren’t on the drug.  The research was published online in the journal Cancer.  Two former OCRF grantees, Jeremy Chien, PhD, and Ramandeep Rattan, PhD, were among the paper’s authors. While metformin (also called Glucophage) … Continued

Physiological Evidence of "Cancer Brain" Found

Physiological Evidence of "Cancer Brain" Found

Using PET/CT scans, researchers looked at the brain function of 128 breast cancer patients. The study aimed to show that PET/CT is a useful tool to measure the presence of chemo brain. Read the abstract here and an article on the study here

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.